J. Kermit Anderson - 07 Apr 2026 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Reporting relationship: Director
Issuer ticker: ADIL
Reported as of: 07 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Apr 2026, 17:00:09 UTC
Prior SEC filing: 02 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ John Martin, Attorney-in-fact for J. Kermit Anderson

Filing notes and source

Key filing fact

J. Kermit Anderson filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 09 Apr 2026.

Key facts

This page summarizes J. Kermit Anderson's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Apr 2026, 17:00.

Change

Previous filing in this sequence was filed on 02 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001717983 Primary reporting owner

Anderson J. Kermit

Relationship: Director
Address: 4870 SADLER ROAD, STE 300, GLEN ALLEN
Signature: /s/ John Martin, Attorney-in-fact for J. Kermit Anderson
Signature date: 09 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +9,185
Change %
Price: $0.000000^*
Shares after: 9,185
Date: 07 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,185
Exercise price: $1.64
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in full on the earlier of (i) the one-year anniversary of the grant date; or (ii) a Change of Control (as defined in the Issuer's 2017 Equity Incentive Plan, as amended), subject to the Reporting Person's continued service to the Issuer through the vesting date.